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Abstract
Background: Severe acute respiratory syndrome (SARS)-CoV is a newly emerging virus that
causes SARS with high mortality rate in infected people. Successful control of the global SARS
epidemic will require rapid and sensitive diagnostic tests to monitor its spread, as well as, the
development of vaccines and new antiviral compounds including neutralizing antibodies that
effectively prevent or treat this disease.
Methods: The human synthetic single-chain fragment variable (scFv) ETH-2 phage antibody library
was used for the isolation of scFvs against the nucleocapsid (N) protein of SARS-CoV using a bio
panning-based strategy. The selected scFvs were characterized under genetics-molecular aspects
and for SARS-CoV N protein detection in ELISA, western blotting and immunocytochemistry.
Results: Human scFv antibodies to N protein of SARS-CoV can be easily isolated by selecting the
ETH-2 phage library on immunotubes coated with antigen. These in vitro selected human scFvs
specifically recognize in ELISA and western blotting studies distinct epitopes in N protein domains
and detect in immunohistochemistry investigations SARS-CoV particles in infected Vero cells.
Conclusion: The human scFv antibodies isolated and described in this study represent useful
reagents for rapid detection of N SARS-CoV protein and SARS virus particles in infected target
cells.
Background
The widespread diffusion and mortality of severe acute
respiratory syndrome (SARS), caused by a new Coronavirus
(SARS-CoV) has threatened the entire world [1] and has
urged the scientific community to develop molecular and
serological tests which can assist for rapid detection of
SARS cases and implementation of control measures [2].
Effective prophylaxis and antiviral therapies are urgently
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needed in the event of re-emergence of the highly conta-
gious and often fatal SARS infection.
Like other known Coronaviruses, SARS-CoV is an envel-
oped virus containing four structural proteins, namely the
membrane (M), envelope (E), spike (S) and the nucleo-
capsid (N) proteins [1]. The N protein is a 423 amino
acid, predicted phospho-protein of 46 kDa, which shares
little homology with other members of the Coronavirus
genus [3,4]. Several studies have found that N protein is
highly immunogenic, thus antibody response in patients
with SARS is directed most frequently and predominantly
to the nucleocapsid. It has also been found that anti N
antibodies are detected early and with high specificity dur-
ing infection [5]. Therefore, the generation of N-specific
reagents, in particular monoclonal antibodies (mAbs)
could be of assistance in studies of viral replication and
antiviral activity, as well as in the diagnosis of SARS-CoV
infection at various disease stages. It has also been found
that SARS patients show clinical improvement if they are
treated with serum from previously infected patients sug-
gesting that passive immunotherapy could be developed
for the treatment of this infectious disease [6]. However,
the traditional approach to generate mAbs to SARS-CoV
has presented difficulties for several reasons including
safety concerns in handling SARS particles [7]. To over-
come these limitations, we applied a very effective and
safe in in vitro procedure based on human scFvs selection
from the large synthetic ETH-2 phage antibody library [8].
Here, we report the identification, production, and
epitope characterization of human scFv antibodies specif-
ically recognizing distinct N protein domains. These
recombinant mAbs were found to bind selectively and
with good affinity to distinct N protein epitopes, and were
suitable to specifically identify SARS particles in Vero
infected cells.
Methods
SARS-CoV antigens
Nucleocapsid (N) protein of SARS-CoV (residues: 1–422)
and its fragments N1 (residues: 1–117), N2 (residues:
110–340) and N3 (residues: 333–422) expressed in E. coli
by DNA recombinant technology as reported by Carattoli,
Di Bonito et al [9]. These polypeptides have proved to
react with specific sera of SARS-CoV infected patients.
ETH-2 antibody phage library
The synthetic human recombinant antibodies library
(ETH-2) consists of a large array (more than 109 antibody
combination) of scFv polypeptides displayed on the sur-
face of M13 phage. It was built by random mutagenesis of
the CDR3 of only three antibody germline gene segments
(DP47 for the heavy chain, DPK22 and DPL16 for the
light chain). Diversity of the heavy chain was created by
randomizing four to six positions replacing the pre-exist-
ing positions 95 to 98 of the CDR3. The diversity of the
light chain was created by randomizing six positions (91
to 96) in the CDR3 [8].
Isolation of phage antibodies from ETH-2 library
An aliquot of the ETH-2 library, containing 1013  cfu
phage, was used to isolate specific human antibodies in
scFv format to SARS-CoV N protein. Immunotubes (Nunc
Maxisorp; Denmark) were coated overnight (ON) at room
temperature (RT) with 10 µg/ml of recombinant purified
SARS-CoV N protein in PBS. After panning, phages were
eluted with 1 ml of 100 mM triethylamine and the solu-
tion was immediately neutralized by adding 0.5 ml of 1 M
Tris-HCl pH 7.4. Eluted phages were used to infect log
phase TG1 E. coli bacteria and amplified for the next
round of selection. Briefly, 50 ml of 2 × YT with 100 µg/
ml ampicillin (2 × YTA medium) and glucose 1% were
inoculated with enough bacterial suspension to yield an
OD600 nm≅ 0.05–0.1. The culture was grown up to OD600
nm 0.4–0.5 and infected with M13 K07 helper phage in a
ratio of around 20:1 phage/bacteria. The rescued phages
were concentrated by precipitation with PEG 6000 and
used for next round of panning (usually three to recover
antigen-specific antibody phages from the ETH-2 library).
For soluble scFv preparation, individual colonies were
grown in 96 flat bottomed wells (Nunc) for 2 hours at
37°C in 180 µl 2 × YTA medium and glucose 0.1% in 96
well plates and inducted with 50 µl 2 × YTA medium and
6 mM IPTG. The following day the plates were spinned
down at 1800 g for 10 minutes and the supernatants con-
taining soluble scFvs were recovered and tested for
specificity.
ELISA
96 well ELISA-plates (Nunc Maxisorp) were coated ON at
RT with 0.5 µg of antigen (N protein or its N1, N2, N3
fragments) in PBS. The following day a blocking solution,
consisting of 2% non fat dry milk in PBS (MPBS), was
added; plates were washed with PBS containing 0.05%
Tween 20 (TPBS) and incubated for 2 hours at RT with 50
µl of supernatants containing soluble scFv antibody, anti-
Flag M2 antibody (1.6 µg/ml Sigma-Aldrich; MO, USA)
and anti-mouse HRP conjugated antibody (1.6 µg/ml
Dako; Denmark). The reaction was developed using 3, 31-
5, 51-tetramethylbenzidin BM blue, POD-substrate solu-
ble (Roche Diagnostics; IN, USA) and stopped by adding
50 µl of 1 M sulfidric acid. The reaction was detected with
an ELISA reader (Biorad; CA, USA), and the results were
expressed as A (absorbance) = A(450 nm)-A(620 nm).
Western blotting
1 µg of SARS-CoV N, N1, N2 and N3 proteins were loaded
onto 12% SDS-PAGE and transferred to a nitrocellulose
membrane using standard procedures. The membrane
was blocked in 4% MPBS ON at RT. Blotted proteins were
incubated for 2 hours with supernatant containingBMC Infectious Diseases 2005, 5:73 http://www.biomedcentral.com/1471-2334/5/73
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soluble scFvs, washed with 0,05% TPBS and incubated
again with 5 µg/ml anti-Flag M2 mouse antibody (Sigma-
Aldrich) in 2% MPBS. After an additional incubation for
1 hour at RT in presence of 5 µg/ml of a goat anti-mouse
antibody HRP-conjugated (Dako), the reaction was devel-
oped and visualized with a chemiluminescence detection
kit (Pierce; IL, USA).
Immunocytochemical determination of SARS-CoV 
particles
BIOCHIP slides (Euroimmun, Luebeck, Germany) coated
with SARS-CoV infected Vero cells were used for immuno-
cytochemistry determination of virus particles by phage or
scFv specific antibodies. Slides were treated for 10 minutes
with peroxidase block solution (Dako En Vision System
HRP), washed in TPBS buffer and incubated for 1 hour at
RT with 1012 phage antibody particles (resuspended in 25
µl of TPBS) or scFv containing supernatant (25 µl). As
control, BIOCHIP slides were incubated with an irrelevant
anti-glucose oxidase phage or scFv antibodies [10]. After
extensive washings with TPBS, the slides were incubated
for 1 hour at RT with an anti-M13 secondary mouse anti-
body (5 µg/ml in 20 µl TPBS) (Amersham) or with an
anti-FLAG secondary mouse antibody (5 µg/ml in 20 µl
TPBS) (Sigma-Aldrich) for labelling phage and scFv reac-
tive antibodies, respectively. After washings, the slides
were treated for 30 minutes at RT with cromogen solu-
tions (Dako) and inspected with a light microscope.
DNA characterization and sequences
Plasmid DNA from individual bacterial colonies of
MA2.D5, MA2.D7 and MA2.E3 clones was digested with
specific endonucleases and CDR3 regions sequenced with
an automated DNA sequencer (M-Medical/Genenco,
Pomezia, Italy) using fdseq1 (5'-GAA TTT TCT GTA TGA
GG-3') and pelBback (5'-AGC CGC TGG ATT GTT ATT
AC-3') primers.
N protein specific scFvs antibodies determined by ELISA Figure 1
N protein specific scFvs antibodies determined by ELISA. IPTG inducted bacterial supernatants of individual colonies 
from the third round of the ETH-2 library selection on N protein were tested in 96-well microtiter plates coated with antigen 
or glucose oxidase (negative control). ELISA readings higher than three fold above negative controls were scored as positive 
reactions. ELISA values of the scFv clones against N protein (panel A) and glucose oxidase (panel B) are shown.
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Results and discussion
Isolation of human scFv antibodies
To isolate specific scFv antibodies, an aliquot of the
human synthetic ETH-2 library containing approximately
1 × 1012 cfu phages was introduced for panning into Max-
isorp immunotubes coated with purified SARS-CoV N
protein as antigen. Non-specifically absorbed phages were
removed by washing. Bound phages were eluted, ampli-
fied and used for the next cycle of panning as described
elsewhere [8,10]. By using this protocol [10], phage anti-
body populations specifically recognizing the N protein
of SARS-CoV were isolated after only three rounds of
selection. Plating on agar of TG1 phage antibody-infected
cells, allowed growth of individual phagemid clones. Sol-
uble scFvs derived from IPTG inducted colonies, were
screened by ELISA and several of them proved to be spe-
cific for N protein (Figure 1).
Epitope recognition
N-positive scFv clones were analysed by ELISA for reactiv-
ity with N1, N2 and N3 protein fragments (Figure 2).
Three distinct classes of scFv antibodies recognizing either
the intact N protein only or also N2 or N3 fragments were
identified. ScFv antibodies recognizing N protein only but
none of its fragments (for instance the MA2D5 scFv) were
likely directed against epitopes encompassing two adja-
cent protein fragments or conformational epitopes
expressed only on the integral protein. The absence of scFv
antibodies reacting with the N1 fragment somewhat
matches the lower antigenicity of this polypeptide, as
compared to immunodominant N2 and N3 fragments,
[9], despite the reported reactivity of several linear syn-
thetic epitopes of the N1 region with SARS sera [11]. How-
ever, a relatively low number of scFv clones were here
tested for a sound conclusion on this aspect.
SARS-CoV particles identification
Three of the most reactive scFv antibody clones named
MA2.D5, MA2.D7 and MA2.E3 each one representing the
different classes of epitope recognition in the N protein
domains were further assessed to verify their biochemical
patterns, reactivity with SARS-CoV infected cells, and
DNA sequences of their encoding genes.
Western blotting analysis (Figure 2) shows that all three
antibodies react with a 46 kDa band corresponding to the
predicted molecular mass of the intact N protein [3]. As
expected by previous ELISA indications, the scFvs MA2.E3
and MA2.D7 recognize also a 28–30 kDa and 12–14 kDa
bands respectively, corresponding to the predicted molec-
ular mass of N protein fragments N2 and N3 [9].
The molecular analysis of the phage antibodies MA2.D5,
MA2.D7 and MA2.E3 shows scFv antibodies with a molec-
ular weight of about 27 kDa and the integrity of the genes
encoding for the cognate scFvs displayed on M13 phage
(data not show). VH and VL gene sequences, shows that
each single scFv antibody clone possess a unique DNA
sequence encoding for the CDR3 region (Figure 3); this
uniqueness is consistent with the distinct epitope recogni-
tion patterns of the three scFvs noted above. Immunocy-
tochemical investigations show that MA2.D5 antibody
specifically recognizes SARS-CoV particles in infected
Vero cells (Figure 4). The other two antibodies MA2.D7
and MA2.E3, though genuinely reacting with N protein
and its N2 and N3 fragments in ELISA and western blot-
ting (see above) did not prove to be useful for SARS-CoV
determination in infected cells.
Conclusion
The usefulness of the library as a tool for generating mon-
oclonal antibodies against viral pathogens [12-14] includ-
ing SARS-CoV [15,16] has been tested and showing that
phage antibodies may recognize viral proteins used as
antigens. In particular, a rodent library has proved to be
very effective for the isolation of murine scFvs exhibiting
high specificity against SARS-CoV E protein, which is rec-
ognized as a 31 kDa protein in western blot studies [15].
Interestingly, one of these clones (A17) isolated by select-
ing the rodent library against the 31 kDa E protein cross-
reacts in ELISA with a well-defined fragment of the 46–48
kDa N protein. Recently, human mAbs were identified by
biopanning of a synthetic library on SARS-CoV lysate; the
isolated scFvs expressed on phages have proved to recog-
nize N protein only in ELISA while no evidences for N
protein recognition in western blot studies or in SARS
infected cells were shown [16]. The efficient display of
recombinant antibodies on filamentous phage has been
also assessed by our findings showing that soluble human
scFvs selected from the ETH-2 library may yield agents
capable of specifically recognizing SARS-CoV particles in
infected Vero cells as well as the intact 46–48 kDa SARS-
CoV N protein and its N2 (28–30 kDa) and N3 (12–14
kDa) fragments in western blot and ELISA investigations
(Figure 2 and 4). To our knowledge, the human scFvs
directed against N protein, by us isolated and character-
ized, are the first antibodies so far described which are
able to detect SARS-CoV N protein in different routinary
laboratory techniques such as ELISA, Western blot and
immunocytochemistry. Hence, these human mAbs repre-
sent excellent candidates for future development of sero-
logical diagnosis of SARS-CoV infections since high
functionality (all clones express soluble antibodies in
bacteria), specificity (all clones recognize the 46–48 kDa
N protein) and quality (all clones give good signals in
ELISA, in western blot as well and stain SARS-CoV
infected cells).
Furthermore, the genes encoding for the selected MA2.D5,
MA2.D7 and MA2.E3 antibodies have been isolated andBMC Infectious Diseases 2005, 5:73 http://www.biomedcentral.com/1471-2334/5/73
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N protein domain recognition by specific scFv antibodies Figure 2
N protein domain recognition by specific scFv antibodies. The scFvs MA2.E3, MA2.D5 and MA2.D7 antibody clones 
showing distinct N protein recognition patterns in an ELISA (A, A', A") were also analyzed for different epitope recognition by 
western blot. While all scFv antibodies react with a 46–48 kDa band corresponding to the MW of the N protein (B, B', B"), the 
scFvs MA2.E3 and MA2.D7 also react with a 28–30 KDa and 12–14 KDa band (B, B") corresponding to the MW of N2 and N3 
protein fragments, respectively.
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Molecular genetics characteristics of the scFv antibodies Figure 3
Molecular genetics characteristics of the scFv antibodies. The nucleotide composition, and the corresponding amino 
acid sequences and residue position in the CDR3 region of the selected scFv antibodies MA2.D5, MA2.D7 and MA2.E5 are 
reported. A schematic representation of the scFv antibodies displayed on M13 phage as pIII fusion proteins is depicted.
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sequenced, thus facilitating various molecular approaches
including site direct mutagenesis to maturate binding
affinity and construct whole recombinant immunoglobu-
lins for SARS-CoV studies and applications. To this latter
regard, another immediate use of human scFv directed to
N protein is through intracellular expression as a novel
strategy of gene therapy aimed at knockout the replicative
cycle of SARS-CoV in infected cells. It is thought that intra-
cellular expression of scFv antibodies may be superior
over alternative methods for gene inactivation such as
anti-sense RNA and dominant negative mutants because
of its high specificity [17,18].
Nevertheless, phage display approach make feasible sev-
eral strategies for the isolation of neutralizing human
mAbs to provide an immediate treatment for emergency
prophylaxis of SARS-CoV [19] while vaccines and new
drugs are underway. For example, immune library may be
constructed and screened on SARS-CoV proteins, using B-
cells from convalescent SARS patients as a genetic source
of specific VH and VL. In alternative, synthetic peptides
mimicking immunodominant epitopes in S or M SARS-
CoV proteins [20] may be used as a substrate antigens for
the identification of specific scFvs from synthetic human
phage antibody library.
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clonal antibodies.
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SARS-CoV detection by MA2.D5 scFv antibody Figure 4
SARS-CoV detection by MA2.D5 scFv antibody. The immunocytochemical detection of SARS-CoV particles in infected 
monkey Vero cells by the MA2.D5 antibody is shown in A (soluble scFv protein) and B (phage displaying scFv antibody). In C 
and D the reactivity of Vero cells with an irrelevant scFv and phage antibody are shown.
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